{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T04:08:59Z","timestamp":1788754139538,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"DOI":"10.1038\/s43856-025-00800-2","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T02:11:53Z","timestamp":1742955113000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Fluctuations in serogroup B meningococcal vaccine antigens prior to routine MenB vaccination in France"],"prefix":"10.1038","volume":"5","author":[{"given":"Micha\u00ebl","family":"Falgui\u00e8res","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Denizon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Terrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhamed-Kheir","family":"Taha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2887-1732","authenticated-orcid":false,"given":"Ala-Eddine","family":"Deghmane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"800_CR1","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1099\/jmm.0.45529-0","volume":"53","author":"SP Yazdankhah","year":"2004","unstructured":"Yazdankhah, S. P. & Caugant, D. A. Neisseria meningitidis: an overview of the carriage state. J. Med. Microbiol. 53, 821\u2013832 (2004).","journal-title":"J. Med. Microbiol."},{"key":"800_CR2","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1017\/S0950268817000929","volume":"145","author":"O Sall","year":"2017","unstructured":"Sall, O. et al. Clinical presentation of invasive disease caused by Neisseria meningitidis serogroup Y in Sweden, 1995 to 2012. Epidemiol. Infect. 145, 2137\u20132143 (2017).","journal-title":"Epidemiol. Infect."},{"key":"800_CR3","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2021.2021764","volume":"18","author":"C Weil-Olivier","year":"2022","unstructured":"Weil-Olivier, C. et al. Care pathways in invasive meningococcal disease: a retrospective analysis of the French national public health insurance database. Hum. Vaccin. Immunother. 18, 2021764 (2022).","journal-title":"Hum. Vaccin. Immunother."},{"key":"800_CR4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40121-021-00546-z","volume":"11","author":"J Shen","year":"2022","unstructured":"Shen, J., Bouee, S., Aris, E., Emery, C. & Beck, E. C. Long-term mortality and state financial support in invasive meningococcal disease-real-world data analysis using the French National Claims database (SNIIRAM). Infect. Dis. Ther. 11, 249\u2013262 (2022).","journal-title":"Infect. Dis. Ther."},{"key":"800_CR5","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/j.jiph.2023.10.001","volume":"16","author":"S Taha","year":"2023","unstructured":"Taha, S. et al. The rapid rebound of invasive meningococcal disease in France at the end of 2022. J. Infect. Public Health 16, 1954\u20131960 (2023).","journal-title":"J. Infect. Public Health"},{"key":"800_CR6","volume":"13","author":"MK Taha","year":"2020","unstructured":"Taha, M. K. & Deghmane, A. E. Impact of COVID-19 pandemic and the lockdown on invasive meningococcal disease. BMC Res. Notes 13, 399 (2020).","journal-title":"BMC Res. Notes"},{"key":"800_CR7","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/14760584.2017.1258308","volume":"16","author":"R Borrow","year":"2017","unstructured":"Borrow, R. et al. The global meningococcal initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Review of Vaccines 16, 313\u2013328 (2017).","journal-title":"Expert Review of Vaccines"},{"key":"800_CR8","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1080\/14760584.2020.1800460","volume":"19","author":"W Luo","year":"2020","unstructured":"Luo, W., Arkwright, P. D. & Borrow, R. Antibody persistence following meningococcal ACWY conjugate vaccine licensed in the European Union by age group and vaccine. Expert Rev. Vaccines 19, 745\u2013754 (2020).","journal-title":"Expert Rev. Vaccines"},{"key":"800_CR9","doi-asserted-by":"crossref","first-page":"7130","DOI":"10.1128\/IAI.69.11.7130-7139.2001","volume":"69","author":"D Coquillat","year":"2001","unstructured":"Coquillat, D. et al. Activity and cross-reactivity of antibodies induced in mice by immunization with a group B meningococcal conjugate. Infect Immun. 69, 7130\u20137139 (2001).","journal-title":"Infect Immun."},{"key":"800_CR10","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1126\/science.287.5459.1816","volume":"287","author":"M Pizza","year":"2000","unstructured":"Pizza, M. et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287, 1816\u20131820 (2000).","journal-title":"Science"},{"key":"800_CR11","doi-asserted-by":"crossref","unstructured":"Shirley, M. & Dhillon, S. Bivalent rLP2086 vaccine (Trumenba): a review in active immunization against invasive meningococcal group B disease in individuals aged 10\u201325 years. BioDrugs 29, 353\u2013361 (2015).","DOI":"10.1007\/s40259-015-0139-0"},{"key":"800_CR12","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Strat\u00e9gie de vaccination pour la pr\u00e9vention des infections invasives \u00e0 m\u00e9ningocoques: Le s\u00e9rogroupe B et la place de Bexsero\u00ae http:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2021-06\/strategie_de_vaccination_pour_la_prevention_des_infections_invasives_a_meningocoques_le_serogroupe_b_et_la_place_de_bexsero.pdf (2021)."},{"key":"800_CR13","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1473-3099(13)70006-9","volume":"13","author":"U Vogel","year":"2013","unstructured":"Vogel, U. et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect. Dis. 13, 416\u2013425 (2013).","journal-title":"Lancet Infect. Dis."},{"key":"800_CR14","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jinf.2020.07.034","volume":"81","author":"R Borrow","year":"2020","unstructured":"Borrow, R. et al. Methods to evaluate serogroup B meningococcal vaccines: from predictions to real-world evidence. J. Infect. 81, 862\u2013872 (2020).","journal-title":"J. Infect."},{"key":"800_CR15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/21645515.2017.1264750","volume":"13","author":"RG Donald","year":"2017","unstructured":"Donald, R. G. et al. Meningococcal serogroup B vaccines: estimating breadth of coverage. Hum. Vaccin. Immunother. 13, 255\u2013265 (2017).","journal-title":"Hum. Vaccin. Immunother."},{"key":"800_CR16","doi-asserted-by":"crossref","unstructured":"McNeil, L. K. et al. Predicting the susceptibility of meningococcal serogroup B isolates to bactericidal antibodies elicited by bivalent rLP2086, a novel prophylactic vaccine. MBio 9, 10-1128 (2018).","DOI":"10.1128\/mBio.00036-18"},{"key":"800_CR17","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.vaccine.2018.12.061","volume":"37","author":"A Muzzi","year":"2019","unstructured":"Muzzi, A. et al. Genetic meningococcal antigen typing system (gMATS): a genotyping tool that predicts 4CMenB strain coverage worldwide. Vaccine 37, 991\u20131000 (2019).","journal-title":"Vaccine"},{"key":"800_CR18","doi-asserted-by":"crossref","unstructured":"Rodrigues, C. M. C. et al. Meningococcal deduced vaccine antigen reactivity (MenDeVAR) index: a rapid and accessible tool that exploits genomic data in public health and clinical microbiology applications. J. Clin. Microbiol. 59, e02161-20 (2020).","DOI":"10.1128\/JCM.02161-20"},{"key":"800_CR19","doi-asserted-by":"crossref","first-page":"5614","DOI":"10.1080\/21645515.2021.2004055","volume":"17","author":"E Hong","year":"2021","unstructured":"Hong, E. et al. Evolution of strain coverage by the multicomponent meningococcal serogroup B vaccine (4CMenB) in France. Hum. Vaccin. Immunother. 17, 5614\u20135622 (2021).","journal-title":"Hum. Vaccin. Immunother."},{"key":"800_CR20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jinf.2021.01.030","volume":"82","author":"R Abad","year":"2021","unstructured":"Abad, R. et al. Molecular characterization of invasive serogroup B Neisseria meningitidis isolates from Spain during 2015-2018: evolution of the vaccine antigen factor H binding protein (FHbp). J. Infect. 82, 37\u201344 (2021).","journal-title":"J. Infect."},{"key":"800_CR21","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jinf.2017.02.011","volume":"74","author":"I Parent du Chatelet","year":"2017","unstructured":"Parent du Chatelet, I. et al. Characteristics and changes in invasive meningococcal disease epidemiology in France, 2006\u20132015. J. Infect. 74, 564\u2013574 (2017).","journal-title":"J. Infect."},{"key":"800_CR22","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2105-11-595","volume":"11","author":"KA Jolley","year":"2010","unstructured":"Jolley, K. A. & Maiden, M. C. BIGSdb: scalable analysis of bacterial genome variation at the population level. BMC Bioinform. 11, 595 (2010).","journal-title":"BMC Bioinform."},{"key":"800_CR23","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/molbev\/msj030","volume":"23","author":"DH Huson","year":"2006","unstructured":"Huson, D. H. & Bryant, D. Application of phylogenetic networks in evolutionary studies. Mol. Biol. Evol. 23, 254\u2013267 (2006).","journal-title":"Mol. Biol. Evol."},{"key":"800_CR24","doi-asserted-by":"crossref","first-page":"e45349","DOI":"10.1371\/journal.pone.0045349","volume":"7","author":"ER Watkins","year":"2012","unstructured":"Watkins, E. R. & Maiden, M. C. Persistence of hyperinvasive meningococcal strain types during global spread as recorded in the PubMLST database. PLoS ONE 7, e45349 (2012).","journal-title":"PLoS ONE"},{"key":"800_CR25","doi-asserted-by":"crossref","unstructured":"Lucidarme, J. et al. Frequent capsule switching in \u2018ultra-virulent\u2019 meningococci\u2014Are we ready for a serogroup B ST-11 complex outbreak? J. Infect. 75, 95\u2013103 (2017).","DOI":"10.1016\/j.jinf.2017.05.015"},{"key":"800_CR26","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.micinf.2005.06.012","volume":"8","author":"M Lancellotti","year":"2006","unstructured":"Lancellotti, M. et al. Conserved virulence of C to B capsule switched Neisseria meningitidis clinical isolates belonging to ET-37\/ST-11 clonal complex. Microbes Infect. 8, 191\u2013196 (2006).","journal-title":"Microbes Infect."},{"key":"800_CR27","first-page":"165","volume":"14","author":"S Antoniotti","year":"2002","unstructured":"Antoniotti, S., Pellissier, V., Sim\u00e9oni, M. C. & Manuel, C. D\u00e9claration obligatoire des maladies infectieuses. Des maladies \u00ab pestilentielles \u00bb aux maladies \u00ab \u00e9mergentes \u00bb 14, 165\u2013178 (2002).","journal-title":"Des maladies \u00ab pestilentielles \u00bb aux maladies \u00ab \u00e9mergentes \u00bb"},{"key":"800_CR28","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jinf.2021.11.015","volume":"84","author":"J Lucidarme","year":"2022","unstructured":"Lucidarme, J. et al. Invasive serogroup B meningococci in England following three years of 4CMenB vaccination\u2014First real-world data. J. Infect. 84, 136\u2013144 (2022).","journal-title":"J. Infect."},{"key":"800_CR29","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.vaccine.2012.10.072","volume":"31","author":"E Hong","year":"2012","unstructured":"Hong, E., Giorgini, D., Deghmane, A. E. & Taha, M. K. Functional impacts of the diversity of the meningococcal factor H binding protein. Vaccine 31, 183\u2013189 (2012).","journal-title":"Vaccine"},{"key":"800_CR30","doi-asserted-by":"crossref","first-page":"19490","DOI":"10.1073\/pnas.1013758107","volume":"107","author":"J Donnelly","year":"2010","unstructured":"Donnelly, J. et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc. Natl. Acad. Sci. USA 107, 19490\u201319495 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00800-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00800-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00800-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T02:12:58Z","timestamp":1742955178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-00800-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["800"],"URL":"https:\/\/doi.org\/10.1038\/s43856-025-00800-2","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"assertion":[{"value":"5 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.E.D. and M.K.T. reported a patent 630133 issued. M.K.T. reported research grants from the GSK group of companies, Pfizer, and Sanofi Pasteur. The other authors have no conflict to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"87"}}